A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)
- Conditions
- Type 2 Diabetes MellitusTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2023-507846-96-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 13299
Have a diagnosis of type 2 diabetes, Have confirmed atherosclerotic cardiovascular disease, HbA1c =7.0% to =10.5%, Body mass index (BMI) =25 kilograms per meter squared (kg/m²)
Have had a major cardiovascular event within the last 60 days, Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2), Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement, Have type 1 diabetes mellitus, Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months, Are currently planning treatment for diabetic retinopathy and/or macular edema, Currently planning a coronary, carotid, or peripheral artery revascularization, Have a history of pancreatitis, Have a history of ketoacidosis or hyperosmolar state/coma, Have a known clinically significant gastric emptying abnormality, have undergone or currently planning any gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery, Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method